Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded Access Trial of Maraviroc in Treatment-Experienced R5 HIV-1 Infection
NL-OMON31084Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of maraviroc in human immunodeficiency virus infection (HIV) and acquired immunodeficiency syndrome (AIDS), sponsored by Pfizer. Primary endpoints: Grade 3 and 4 adverse events, Serious adverse events and 3 more. Started Oct 2007; status: active, not recruiting.
02
Drugs
maraviroc
03
Conditions
human immunodeficiency virus infection (HIV)acquired immunodeficiency syndrome (AIDS)
Beyond the preview
Go deeper on NL-OMON31084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31084.